SG11201906132UA - Insoluble complex or solvate thereof, pharmaceutical composition and use thereof - Google Patents
Insoluble complex or solvate thereof, pharmaceutical composition and use thereofInfo
- Publication number
- SG11201906132UA SG11201906132UA SG11201906132UA SG11201906132UA SG 11201906132U A SG11201906132U A SG 11201906132UA SG 11201906132U A SG11201906132U A SG 11201906132UA SG 11201906132U A SG11201906132U A SG 11201906132UA
- Authority
- SG
- Singapore
- Prior art keywords
- solvate
- pharmaceutical composition
- insoluble complex
- insoluble
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710188001 | 2017-03-27 | ||
| PCT/CN2018/080424 WO2018177232A1 (zh) | 2017-03-27 | 2018-03-26 | 难溶性复合物或其溶剂合物、药物组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906132UA true SG11201906132UA (en) | 2019-10-30 |
Family
ID=63675241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906132U SG11201906132UA (en) | 2017-03-27 | 2018-03-26 | Insoluble complex or solvate thereof, pharmaceutical composition and use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11084790B2 (zh) |
| EP (1) | EP3486233B1 (zh) |
| JP (1) | JP6923122B2 (zh) |
| KR (1) | KR102248445B1 (zh) |
| CN (1) | CN109996787B (zh) |
| AU (1) | AU2018241564B2 (zh) |
| CA (1) | CA3049220C (zh) |
| DK (1) | DK3486233T3 (zh) |
| EA (1) | EA039449B1 (zh) |
| ES (1) | ES2866401T3 (zh) |
| HU (1) | HUE053472T2 (zh) |
| PH (1) | PH12019501560A1 (zh) |
| PL (1) | PL3486233T3 (zh) |
| PT (1) | PT3486233T (zh) |
| SG (1) | SG11201906132UA (zh) |
| TW (1) | TWI740045B (zh) |
| WO (1) | WO2018177232A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110483372A (zh) * | 2018-05-14 | 2019-11-22 | 南京诺瑞特医药科技有限公司 | 布比卡因的盐 |
| CN111983052B (zh) * | 2020-07-24 | 2023-03-31 | 合肥诺明药物安全研究有限公司 | 一种hyr-pb21有效成分血药浓度的定量分析方法 |
| KR20230133595A (ko) | 2022-03-11 | 2023-09-19 | 한국한의약진흥원 | 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003099293A1 (en) | 2002-05-23 | 2003-12-04 | Danmarks Farmaceutiske Universitet | Pharmacologically active salts |
| US20070110804A1 (en) | 2003-06-20 | 2007-05-17 | Royer Biomedical, Inc. | Drug polymer complexes |
| SI2415484T1 (sl) * | 2004-09-17 | 2014-10-30 | Durect Corporation | Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem |
| US8920843B2 (en) | 2007-11-07 | 2014-12-30 | Svip5 Llc | Slow release of organic salts of local anesthetics for pain relief |
| EP2398468B1 (en) | 2009-02-17 | 2016-11-30 | KRKA, D.D., Novo Mesto | Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation |
| CZ2009762A3 (cs) | 2009-11-16 | 2011-05-25 | Zentiva, K. S. | Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby |
| CN104370934B (zh) | 2013-08-13 | 2018-04-06 | 上海科胜药物研发有限公司 | 一种普拉格雷盐及其制备方法 |
| CN107848973A (zh) | 2015-09-01 | 2018-03-27 | 四川海思科制药有限公司 | S‑(‑)‑1‑丙基‑2’,6’‑二甲苯胺甲酰基哌啶晶体及其缓释制剂 |
| CN110325179A (zh) | 2016-12-26 | 2019-10-11 | 塞尔利克斯生物私人有限公司 | 用于治疗慢性疼痛的组合物和方法 |
-
2018
- 2018-03-26 AU AU2018241564A patent/AU2018241564B2/en active Active
- 2018-03-26 DK DK18777940.0T patent/DK3486233T3/da active
- 2018-03-26 EA EA201990419A patent/EA039449B1/ru unknown
- 2018-03-26 EP EP18777940.0A patent/EP3486233B1/en active Active
- 2018-03-26 JP JP2019535272A patent/JP6923122B2/ja active Active
- 2018-03-26 HU HUE18777940A patent/HUE053472T2/hu unknown
- 2018-03-26 CN CN201880002853.5A patent/CN109996787B/zh active Active
- 2018-03-26 WO PCT/CN2018/080424 patent/WO2018177232A1/zh unknown
- 2018-03-26 US US16/325,997 patent/US11084790B2/en active Active
- 2018-03-26 ES ES18777940T patent/ES2866401T3/es active Active
- 2018-03-26 PL PL18777940T patent/PL3486233T3/pl unknown
- 2018-03-26 KR KR1020197018905A patent/KR102248445B1/ko active IP Right Grant
- 2018-03-26 CA CA3049220A patent/CA3049220C/en active Active
- 2018-03-26 SG SG11201906132U patent/SG11201906132UA/en unknown
- 2018-03-26 PT PT187779400T patent/PT3486233T/pt unknown
- 2018-05-22 TW TW107117420A patent/TWI740045B/zh active
-
2019
- 2019-07-02 PH PH12019501560A patent/PH12019501560A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020515513A (ja) | 2020-05-28 |
| ES2866401T3 (es) | 2021-10-19 |
| EA201990419A1 (ru) | 2019-09-30 |
| EP3486233B1 (en) | 2021-01-27 |
| JP6923122B2 (ja) | 2021-08-18 |
| EA039449B1 (ru) | 2022-01-28 |
| KR102248445B1 (ko) | 2021-05-04 |
| AU2018241564A1 (en) | 2019-05-30 |
| EP3486233A1 (en) | 2019-05-22 |
| TW201940170A (zh) | 2019-10-16 |
| CA3049220C (en) | 2022-03-29 |
| PL3486233T3 (pl) | 2021-06-28 |
| WO2018177232A1 (zh) | 2018-10-04 |
| CN109996787B (zh) | 2022-07-05 |
| CA3049220A1 (en) | 2018-10-04 |
| PT3486233T (pt) | 2021-03-18 |
| DK3486233T3 (da) | 2021-03-15 |
| HUE053472T2 (hu) | 2021-06-28 |
| US11084790B2 (en) | 2021-08-10 |
| PH12019501560A1 (en) | 2020-02-24 |
| US20210087144A1 (en) | 2021-03-25 |
| CN109996787A (zh) | 2019-07-09 |
| EP3486233A4 (en) | 2020-04-08 |
| AU2018241564B2 (en) | 2020-07-02 |
| TWI740045B (zh) | 2021-09-21 |
| KR20190101980A (ko) | 2019-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269061A (en) | A pharmaceutical preparation containing Selexifag | |
| IL271226A (en) | medical preparation | |
| EP3434285A4 (en) | PHARMACEUTICAL COMPOSITION AND USES THEREOF | |
| HK1256674A1 (zh) | 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途 | |
| IL273339A (en) | Griseofulbin compound and its medical use | |
| IL248785B (en) | Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents | |
| PT3606511T (pt) | Composição farmacêutica compreendendo mesilato de lenvatinib | |
| EP3773654C0 (en) | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS | |
| IL248773B (en) | History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them | |
| SG11201906132UA (en) | Insoluble complex or solvate thereof, pharmaceutical composition and use thereof | |
| HK1245113A1 (zh) | 藥物組合物及其用途 | |
| SI3601277T1 (sl) | Farmacevtska formulacija | |
| IL262929B1 (en) | Preparations for treatment, methods of their preparation and their uses | |
| IL275144A (en) | Pharmacy preparation | |
| ZA202000959B (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
| EP3718543A4 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE | |
| IL237283A0 (en) | Dldh and its derivatives, and preparations containing them for medical use | |
| HK1254527A1 (zh) | 藥物調配物和其用途 | |
| GB201713920D0 (en) | Pharmaceutical compositions and uses thereof | |
| GB201812022D0 (en) | Pharmaceutical methods and compositions | |
| GB201719873D0 (en) | Pharmaceutical formulation |